A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- BRAF V600E
- Glioblastoma
- Glioma
- Pleomorphic Xantho-Astrocytoma
- Type
- Observational
- Design
- Observational Model: Case-OnlyTime Perspective: Prospective
Participation Requirements
- Age
- Between 6 years and 125 years
- Gender
- Both males and females
Description
The primary goal of this study is to establish concentrations of dabrafenib and trametinib in enhancing brain tissue and cerebrospinal fluid from people with BRAF-V600E mutant recurrent gliomas who undergo tumor resection. The exploratory goals are to measure the amount of ERK signaling pathway acti...
The primary goal of this study is to establish concentrations of dabrafenib and trametinib in enhancing brain tissue and cerebrospinal fluid from people with BRAF-V600E mutant recurrent gliomas who undergo tumor resection. The exploratory goals are to measure the amount of ERK signaling pathway activity, to identify mechanisms of resistance to these drugs, and evaluate feasibility of measuring tumor DNA in cerebrospinal fluid. People (adults or children) with brain tumors who are already taking dabrafenib and / or trametinib and are in need of a surgical resection are potentially eligible. On the day of surgery, blood, cerebrospinal fluid, and tumor tissue will be collected for research purposes.
Tracking Information
- NCT #
- NCT03593993
- Collaborators
- Musella Foundation
- Investigators
- Principal Investigator: Stuart Grossman, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Principal Investigator: Karisa Schreck, MD, PhD Johns Hopkins School of Medicine
Get Well Soon